Trials
2 active
6 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Narcolepsy
- Main trialPhase 2
- “The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured from the first 4 maintenance of wakefulness tests \[MWTs\]).”In the company’s words, NCT07493265 on ClinicalTrials.gov
Other drugs for Narcolepsy
- OveporextonTakeda · Phase 3
- ALKS 2680Alkermes, Inc. · Phase 3
- CleminorextonCentessa Pharmaceuticals (UK) Limited · Phase 2/3
- PitolisantHarmony Biosciences · Phase 3
- SamelisantSuven Life Sciences Limited · Phase 3
- XywavJazz Pharmaceuticals · Phase 3
Coming up1
- 14 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 14 Feb 2027 | A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy | |
| Phase 1Recruiting | 12 Nov 2026 | A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants | |
| Phase 1Completed | 18 Jan 2024 | A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants | |
| Phase 1Completed | 13 Dec 2024 | A Study of E2086 in Healthy Adult Participants | |
| Phase 1Completed | 17 Mar 2025 | A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1 | |
| Phase 1Completed | 12 Jun 2026 | A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026